AstraZeneca: Bydureon EXSCEL Trial Meets Primary Safety Goal In Type-2 Diabetes - Nasdaq

pharmaphorum

AstraZeneca: Bydureon EXSCEL Trial Meets Primary Safety Goal In Type-2 Diabetes Nasdaq (RTTNews.com) - AstraZeneca plc (AZN.L, AZN) announced Tuesday that Phase IIIb/IV EXenatide Study of Cardiovascular Event Lowering or EXSCEL trial with Bydureon met primary safety objection in type-2 diabetes patients at wide range of ... AstraZeneca Shares Rise as Investors Shrug Off Mixed Diabetes ResultsTheStreet.com AZ's Bydureon disappoints in diabetes outcomes trialpharmaphorum AstraZeneca diabetes trial meets safety objectiveDIGITALLOOK London South East (registration) (blog) all 6 news articles »